A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2019
At a glance
- Drugs Canakinumab (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CANOPY-2
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 25 Jan 2019 Planned initiation date changed from 21 Dec 2018 to 31 Jan 2019.
- 25 Jan 2019 Planned End Date changed from 20 Aug 2021 to 19 Aug 2021.
- 16 Dec 2018 Planned End Date changed from 6 Aug 2021 to 20 Aug 2021.